- Report
- April 2026
- 135 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- April 2026
- 144 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- September 2026
- 477 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- August 2026
- 102 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- August 2026
- 187 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 180 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 195 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- January 2026
- 159 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- January 2026
- 160 Pages
Global
From €4540EUR$4,995USD£3,904GBP
- Report
- May 2026
- 156 Pages
Global
From €3590EUR$3,950USD£3,087GBP
- Report
- May 2026
- 152 Pages
Global
From €3590EUR$3,950USD£3,087GBP
- Report
- November 2025
- 150 Pages
Global
From €4409EUR$4,850USD£3,790GBP
- Report
- August 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- August 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- August 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- August 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- July 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- July 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- January 2026
- 160 Pages
Global
From €2872EUR$3,160USD£2,470GBP
€3590EUR$3,950USD£3,087GBP
- Report
- October 2025
- 160 Pages
Global
From €2872EUR$3,160USD£2,470GBP
€3590EUR$3,950USD£3,087GBP

The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more